SCHEMBL4866091

SCHEMBL4866091

CCSc1nc(NC(C)C)c2ccccc2n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.57
ACP1 P24666 1/20 0.56
TLR7 Q9NYK1 1/20 0.54
KDM4E B2RXH2 4/20 0.48
LMNA P02545 2/20 0.48
BCHE P06276 2/20 0.47
ACHE P22303 2/20 0.47
MAPK1 P28482 1/20 0.44
KMT2A Q03164 4/20 0.43
MAPT P10636 4/20 0.43
MEN1 O00255 3/20 0.43
HTT P42858 2/20 0.43
HIF1A Q16665 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
TP53 P04637 1/20 0.41
ELANE P08246 2/20 0.41
ALDH1A1 P00352 2/20 0.41
ABCB1 P08183 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4868605 0.89 MEN1 (0.56) APPACP1TLR7KDM4ELMNA
SCHEMBL5108077 0.87 MAPT (0.59) KDM4ELMNAKMT2AMAPTMEN1
SCHEMBL4866137 0.83 ACP1 (0.60) APPACP1TLR7KDM4ELMNA
SCHEMBL4865087 0.80 MAPT (0.42) TLR7KDM4ELMNAMAPK1KMT2A
SCHEMBL4863793 0.78 APP (0.62) APPKDM4ELMNABCHEACHE
SCHEMBL4867312 0.78 ACP1 (0.58) ACP1TLR7KDM4EKMT2AMEN1
SCHEMBL4867045 0.77 ACP1 (0.63) APPACP1TLR7KDM4ELMNA
SCHEMBL4865325 0.77 MAPK1 (0.57) APPKDM4ELMNAMAPK1KMT2A
SCHEMBL4860001 0.77 PDE5A (0.59) ACP1TLR7KDM4ELMNAKMT2A
SCHEMBL4864291 0.76 KDM4E (0.53) APPKDM4ELMNABCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US claimed
JP-2008526734-A 2008-07-24 JP claimed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP claimed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO claimed
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US disclosed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP disclosed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY GPR119, GCKR, GLP1R APP 4386/4885ACP1 3203/4885TLR7 913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.